Merck Acquires Bio-Techne for $73 Per Share
Merck (MRK) announced the acquisition of Bio-Techne (TECH) for $73 per share in cash, totaling approximately $11 billion. The deal gives Merck a platform in life sciences tools and diagnostics, and represents a premium over TECH's previous closing price.
Key Numbers
Merck (MRK) announced today it will acquire Bio-Techne (TECH), a life sciences tools and diagnostics company, for $73 per share in cash, totaling approximately $11 billion. TECH shares rallied on the news, while MRK shares edged slightly lower.
Deal Details
| Item | Value |
|---|---|
| Acquisition price | $73 per share |
| Total value | $11 billion |
| Payment method | All cash |
| Premium over prior close | Not disclosed (per source) |
| Expected closing | First half of 2026 |
Rationale for the Deal
Merck aims to strengthen its presence in the fast-growing life sciences tools and diagnostics sector. Bio-Techne's portfolio of protein and cell analysis products complements Merck's pharmaceutical and vaccine business.
Regulatory Hurdles
The deal is expected to face regulatory review in the U.S. and Europe due to its size and potential impact on competition. Merck has not flagged any specific regulatory concerns.
Impact on Stocks
TECH shares surged today, reflecting market optimism about the deal's value. In contrast, MRK shares dipped slightly, possibly due to concerns over the high acquisition cost. Some analysts see the deal boosting Merck's long-term growth.
Frequently Asked Questions
Found this useful? Share it